ID
29422
Description
Study ID: 102587 Clinical Study ID: EGF102587 Study Title: A Single-Dose, Open-Label, Randomized, Three-Way Cross-Over Study in Healthy Subjects to Evaluate the Relative Bioequivalence of Two New Small Tablet Formulations of Lapatinib (GW572016) Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tykerb,Tycerb,Tyverb; Tyverb,Tykerb,Tycerb Study Indication: Neoplasms, Breast Documentation part: Consent for PGx-Pharmacogenetic research
Keywords
Versions (1)
- 3/22/18 3/22/18 -
Copyright Holder
GlaxoSmithKline
Uploaded on
March 22, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
GSK Study to Evaluate the Relative Bioequivalence of Two New Small Tablet Formulations of Lapatinib in Healthy Subjects 102587
Consent for PGx-Pharmacogenetic research
- StudyEvent: ODM
Similar models
Consent for PGx-Pharmacogenetic research
- StudyEvent: ODM
C2347500 (UMLS CUI-2)
C0008976 (UMLS CUI-3)
C2347500 (UMLS CUI [1,2])
C1882120 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,3])
C1882120 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,3])
C2347500 (UMLS CUI [1,2])
C1948029 (UMLS CUI [1,2])
C1272683 (UMLS CUI [1,3])
C0178913 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,3])
C0178913 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,3])